In the Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI) study, the nuclear factor erythroid 2-related factor 2 activator, bardoxolone methyl, demonstrated an enhancement in the GFR among patients suffering from DKD [94]. This evidence concerns the gene NFE2L2 and diabetic kidney disease.